FAZE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of FaZe Holdings Inc. Is Fair to Shareholders
NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of FaZe Holdings Inc. (NASDAQ: FAZE) to GameSquare... Read more.
Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
At a pre-specified interim analysis in LITESPARK-005, WELIREG reduced the risk of disease progression or death compared to everolimus First Phase 3 trial to show... Read more.
DFS LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Discover Financial Services Investors to Secure Counsel Before Important Deadline in Securities Class Action – DFS
NEW YORK–(BUSINESS WIRE)–$DFS #DFS—WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Discover Financial... Read more.
CHNT Group Showed at The 24th Conference on The Electric Power Supply Industry
XIAMEN, China–(BUSINESS WIRE)–On October 20th, the 24th Conference on The Electric Power Supply Industry kicked off in Xiamen, attended by more than... Read more.
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
IMFINZI reduced the risk of disease progression or death by 29% vs. chemotherapy First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP... Read more.
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
59% of these patients treated with TAGRISSO plus chemotherapy had complete brain tumor responses in FLAURA2 Phase III trial WILMINGTON, Del.–(BUSINESS WIRE)–Results... Read more.
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis’ MRD Technology
NeXT Personal® ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients Demonstrates importance of an ultra-sensitive... Read more.
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced... Read more.
AnHeart Therapeutics’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial
Taletrectinib also shrank tumors in 57 percent of people with ROS1-positive NSCLC who had previously been treated with a ROS1 TKI in the trial Taletrectinib continues... Read more.
MakeMyTrip Limited to report Fiscal 2024 Second Quarter Financial & Operating Results on October 31, 2023
GURUGRAM, India & NEW YORK–(BUSINESS WIRE)–$MMYT #Fiscal2024–MakeMyTrip Limited (Nasdaq: MMYT) plans to report its fiscal 2024 second quarter... Read more.